Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company”), the board of directors of the Company (the “Board”) appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.